Literature DB >> 8486420

Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.

T Boon1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8486420     DOI： 10.1002/ijc.2910540202

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  22 in total

1.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

2.  Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach.

Authors:  Ramziya Kiyamova; Olga Kostianets; Sergey Malyuchik; Valeriy Filonenko; Vasiliy Usenko; Vadym Gurtovyy; Yuliya Khozayenko; Stepan Antonuk; Lloyd Old; Ivan Gout
Journal:  Mol Biotechnol       Date:  2010-10       Impact factor: 2.695

Review 3.  Immune correlates of clinical outcome in melanoma.

Authors:  Graham Pawelec
Journal:  Immunology       Date:  2017-12-20       Impact factor: 7.397

Review 4.  Peptide binding to MHC class I molecules: implications for antigenic peptide prediction.

Authors:  K C Parker; M Shields; M DiBrino; A Brooks; J E Coligan
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 5.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 6.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

7.  Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.

Authors:  A McAllister; A E Arbetman; S Mandl; C Peña-Rossi; R Andino
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Authors:  Jeffrey A Sosman; Carole Carrillo; Walter J Urba; Lawrence Flaherty; Michael B Atkins; Joseph I Clark; Janet Dutcher; Kim A Margolin; James Mier; Jarod Gollob; John M Kirkwood; David J Panka; Nancy A Crosby; Kevin O'Boyle; Bonnie LaFleur; Marc S Ernstoff
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

10.  Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.

Authors:  M L Salgaller; J S Weber; S Koenig; J R Yannelli; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.